Strathspey Crown Holdings Group, LLC - Jul 21, 2023 Form 3 Insider Report for AEON Biopharma, Inc. (AEON)

Role
10%+ Owner
Signature
Strathspey Crown Holdings Group, LLC, By: /s/ Andrew Lusk, Attorney-in-Fact for Robert E. Grant, Manager of Strathspey Crown Group Holdings, LLC
Stock symbol
AEON
Transactions as of
Jul 21, 2023
Transactions value $
$0
Form type
3
Date filed
7/31/2023, 06:39 PM
Next filing
Aug 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AEON Class A Common Stock 9.42M Jul 21, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects (a) 3,416,359 shares (the "Debt Conversion Lock-Up Shares") of the Issuer's Class A common stock, par value $0.0001 per share ("Class A Common Stock"), issued upon the conversion of debt held by the Reporting Person, which shares are subject to a one-year lockup period from the date of issuance pursuant to the Issuer's Amended and Restated Bylaws (the "A&R Bylaws"); (b) 3,821,256 shares of Class A Common Stock issued upon the conversion of debt held by the Reporting Person, which shares are free from any lockup restrictions; and (c) 2,182,755 shares of Class A Common Stock issued upon conversion of shares of Old AEON's (as defined below) equity held by the Reporting Person, which shares are subject to a one-year lockup period from the date of issuance pursuant to the A&R Bylaws (collectively with the Debt Conversion Lock-Up Shares, the "Lock-Up Shares").
F2 (continued from footnote [1]). The foregoing transactions were consummated, and all shares of Class A Common Stock held by the Reporting Person reported herein were acquired, pursuant to a business combination agreement, dated December 12, 2022, by and among Priveterra Acquisition Corp., a Delaware corporation ("Priveterra"), Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra ("Merger Sub"), and AEON Biopharma, Inc., a Delaware corporation ("Old AEON"), pursuant to which Merger Sub was merged with and into Old AEON, with Old AEON surviving the merger as a wholly owned subsidiary of Priveterra, effective as of July 21, 2023 (the "Closing Date"). Upon the closing of the merger, Priveterra changed its name to "AEON Biopharma, Inc."
F3 (continued from footnote [2]). The Reporting Person may not sell, assign, or transfer any of its Lock-Up Shares, subject to certain permitted transfers, until the earliest of (a) the one-year anniversary of the Closing Date, and (b) the date upon which there occurs the completion of a liquidation, merger, stock exchange, reorganization, or other similar transaction that results in all of the public stockholders of the Issuer having the right to exchange its Class A Common Stock for cash, securities, or other property, subject to certain conditions set forth in the A&R Bylaws.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney